Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (8258)	1/9/1999 10:05:00 AM
From: aknahow	Respond to of 17367

On your other subject, XOMA just got a payment of $2,000,000. I am sure that is not what you are talking about, but not sure what you are talking about. The bright side of the confusion, I and perhaps others have over hu1124, is that we seem to all be assured there will be P III trials, because the results thus far were positive. And importantly regardless of who does the trial XOMA does have the option of payment or profit sharing if a product is approved at sometime in the indefinite future.

To: Robert K. who wrote (8258)	1/10/1999 11:51:00 PM
From: Cacaito	Respond to of 17367

Gne, biggest recombinant facility, well most of their products are of the recombinant protein production type. But BPI is also a recombinant protein, noticed the little R: rBPI in many reports, it means recombinant. Just for fun, all dysclaimers apply. invest at your own risk. I am cacaito, Ltd. No claims allow in Bermuda.

To: Robert K. who wrote (8258)	1/13/1999 5:29:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Bob, while much of this new patent probably is similar to items in previous patents I think it makes interesting reading. Would like to see the next drug into clinic be Mycoprex but it probably won't be since they are looking for a partner for this drug. "An advantage provided by the present invention is the ability to treat fungal infections, particularly Candida infections, that are presently considered incurable. Another advantage is the ability to treat fungi that have acquired resistance to known anti-fungal agents. A further advantage of concurrent administration of Domain III derived peptide with an anti-fungal agent having undesirable side effects, e.g., amphotericin B, is the ability to reduce the amount of anti-fungal agent needed for effective therapy. The present invention may also provide quality of life benefits due to, e.g., decreased duration of therapy, reduced stay in intensive care units or reduced stay overall in the hospital, with the concomitant reduced risk of serious nosocomial (hospital-acquired) infections."